Academic Journals Database
Disseminating quality controlled scientific knowledge

Development of a drug safety ePlatform for physicians, pharmacists, and consumers based on post-marketing adverse events

ADD TO MY LIST
 
Author(s): Keith B. Hoffman | Brian M. Overstreet | P. Murali Doraiswamy

Journal: Drugs and Therapy Studies
ISSN 2038-9493

Volume: 3;
Issue: 1;
Start page: e4;
Date: 2013;
Original page

Keywords: patient safety | adverse events | side effects | drug safety | post-marketing | FDA | FAERS | AERS

ABSTRACT
Rigorous clinical trials under the watchful eye of regulators remain the cornerstone of drug safety. However, the emergence of serious and life-threatening Adverse Events (AEs) across best-selling drug classes [sometimes many years after winning Food and Drug Administration (FDA) approval] underscores the limitations of current clinical trial processes and reinforces the need for careful post-approval pharmacovigilance. The FDA’s sizeable repository of patient case reports linking AEs to approved drugs is the Adverse Event Reporting System (FAERS). We believe that open and user-friendly access to the millions of case reports in FAERS would help advance the field of post-marketing pharmacovigilance. However, FAERS data are virtually inaccessible to most physicians, pharmacists, and consumers. Accordingly, we have recently launched a big data platform (www.AdverseEvents.com) that, unlike previous efforts, provides on-demand, user-friendly, and high-impact access to FAERS data. Bringing the power of big data to regular users, such as clinicians, pharmacists, and patients, is the logical next step in the transformation of health care to a model of shared decision making between consumers and the system.
Affiliate Program     

Tango Jona
Tangokurs Rapperswil-Jona